{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T19:01:13Z","timestamp":1792522873277,"version":"4.5.0"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,12,2]],"date-time":"2020-12-02T00:00:00Z","timestamp":1606867200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Although aripiprazole and risperidone are used widespread in pediatrics, there are still limited pieces of evidence on their actual safety profile. By using the EudraVigilance database, we carried out an analysis to perform a comprehensive overview of reported adverse events among children and adolescents treated with aripiprazole and risperidone.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> Descriptive analysis was performed of all individual case safety reports (ISCRs) submitted to EudraVigilance associated with aripiprazole and risperidone and related to the pediatric population from 2016 to 2018.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> A total of 855 and 2,242 ISCRs for aripiprazole and risperidone, respectively, were recorded for a total of 11,042 suspected adverse drug reactions (2,993 for aripiprazole and 8,049 for risperidone). Most ISCRs were related to male patients (65.0 and 86.3% for aripiprazole and risperidone, respectively) and were serious (81.0 and 94.1% for aripiprazole and risperidone, respectively). Schizophrenia spectrum and other psychotic disorders, such as disruptive, impulse-control, and conduct disorders, and autism spectrum disorder were the top three clinical indications for aripiprazole (19.0, 16.1, and 11.6%, respectively). For risperidone, attention-deficit\/hyperactivity disorder (25.4%), disruptive, impulse-control, and conduct disorders (17.1%), and bipolar and related disorders (14.2%) were more commonly reported as clinical indications. Data also showed a high proportion of use for clinical conditions not authorized in children. Psychiatric disorders were the main related adverse events for aripiprazole (20.2%), and among these, suicidal behavior was one of the most reported (14.9%). Reproductive system and breast disorders were the main related adverse events for risperidone (19.8%), and gynecomastia was the most reported event; metabolism and nutrition disorders, mainly reported as weight gain disorders, were more reported in children (3\u201311 years) than in adolescents (12\u201317 years).<\/jats:p><jats:p><jats:bold>Conclusions:<\/jats:bold> Our results demonstrate that spontaneously reported adverse events associated with aripiprazole and risperidone reflect what is already known in terms of safety profile, although with about 90% of them being serious. This analysis stresses the need for further studies and effective training and information activities to better define the actual benefit\/risk ratio of these drugs in pediatric patients.<\/jats:p>","DOI":"10.3389\/fpsyt.2020.550201","type":"journal-article","created":{"date-parts":[[2020,12,2]],"date-time":"2020-12-02T04:45:55Z","timestamp":1606884355000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":16,"title":["We Really Need Clear Guidelines and Recommendations for Safer and Proper Use of Aripiprazole and Risperidone in a Pediatric Population: Real-World Analysis of EudraVigilance Database"],"prefix":"10.3389","volume":"11","author":[{"given":"Concetta","family":"Rafaniello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Giuseppa","family":"Sullo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Carnovale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Pozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Stelitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Radice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato","family":"Bernardini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Clementi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Capuano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,12,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1001\/archpsyc.63.6.679","article-title":"National trends in the outpatient treatment of children and adolescents with antipsychotic drugs","volume":"63","author":"Olfson","year":"2006","journal-title":"Arch Gen Psychiatry."},{"key":"B2","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1177\/070674371205701202","article-title":"A review of pharmacoepidemiologic studies of antipsychotic use in children and adolescents","volume":"57","author":"Patten","year":"2012","journal-title":"Can J Psychiatry."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/j.euroneuro.2019.10.006","article-title":"Incidence of adverse events in antipsychotic-na\u00efve children and adolescents treated with antipsychotic drugs: results of a multicentre naturalistic study (ETAPE)","volume":"29","author":"Menard","year":"2019","journal-title":"Eur Neuropsychopharmacol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jaac.2016.10.005","article-title":"Trends in antipsychotic prescribing in medicaid-eligible youth","volume":"56","author":"Edelsohn","year":"2017","journal-title":"J Am Acad Child Adolesc Psychiatry."},{"key":"B5","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1001\/jamapsychiatry.2015.0500","article-title":"Treatment of young people with antipsychotic medications in the United States","volume":"72","author":"Olfson","year":"2015","journal-title":"JAMA Psychiatry."},{"key":"B6","doi-asserted-by":"publisher","first-page":"e3784","DOI":"10.1097\/MD.0000000000003784","article-title":"National trends in offlabel use of atypical antipsychotics in children and adolescents in the United States","volume":"95","author":"Sohn","year":"2016","journal-title":"Medicine."},{"key":"B7","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.euroneuro.2010.07.002","article-title":"Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: comprehensive review of prospective head-to-head and placebo-controlled comparisons","volume":"21","author":"Fraguas","year":"2011","journal-title":"Eur Neuropsychopharmacol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.4088\/JCP.v69n0717","article-title":"Metabolic and hormonal side effects in children and adolescents treated with second-generation antipsychotics","volume":"69","author":"Fraguas","year":"2008","journal-title":"J Clin Psychiatry."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1001\/jama.2009.1549","article-title":"Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents","volume":"302","author":"Correll","year":"2009","journal-title":"JAMA."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/PRS.0b013e3182361efd","article-title":"The psychological burden of idiopathic adolescent gynecomastia","volume":"129","author":"Kinsella","year":"2012","journal-title":"Plast Reconstr Surg."},{"key":"B11","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1002\/wps.20567","article-title":"Management of common adverse effects of antipsychotic medications","volume":"17","author":"Stroup","year":"2018","journal-title":"World Psychiatry."},{"key":"B12","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1089\/cap.2018.0092","article-title":"Weight-change trajectories of pediatric outpatients treated with risperidone or aripiprazole in a naturalistic setting","volume":"29","author":"Pozzi","year":"2019","journal-title":"J Child Adolesc Psychopharmacol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1186\/s12888-015-0688-2","article-title":"Pharmacological interventions for challenging behavior in children with intellectual disabilities: a systematic review and meta-analysis","volume":"15","author":"McQuire","year":"2015","journal-title":"BMC Psychiatr."},{"key":"B14","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1089\/cap.2018.0111","article-title":"No differences in weight gain between risperidone and aripiprazole in children and adolescents after 12 months","volume":"29","author":"Schoemakers","year":"2019","journal-title":"J Child Adolesc Psychopharmacol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1038\/tpj.2017.38","article-title":"The predictive value of ABCB1, ABCG2, CYP3A4\/5 and CYP2D6 polymorphisms for risperidone and aripiprazole plasma concentrations and the occurrence of adverse drug reactions","volume":"18","author":"Rafaniello","year":"2018","journal-title":"Pharmacogenomics J."},{"key":"B16","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s40264-018-0647-1","article-title":"EudraVigilance medicines safety database: publicly accessible data for research and public health protection","volume":"41","author":"Postigo","year":"2018","journal-title":"Drug Saf."},{"key":"B17","doi-asserted-by":"publisher","first-page":"305","DOI":"10.3389\/fphar.2017.00305","article-title":"Campania Preventability Assessment Committee (Italy): a focus on the preventability of non-steroidal anti-inflammatory drugs' adverse drug reactions","volume":"8","author":"Sessa","year":"2017","journal-title":"Front Pharmacol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1080\/14740338.2016.1225720","article-title":"No substantial gender differences in suspected adverse reactions to ACE inhibitors and ARBs: results from spontaneous reporting system in Campania Region","volume":"15","author":"Sportiello","year":"2016","journal-title":"Expert Opin Drug Saf."},{"key":"B19","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1089\/cap.2018.0139","article-title":"Reported adverse drug reactions in children and adolescents treated with antipsychotics","volume":"29","author":"Minjon","year":"2019","journal-title":"J Child Adolesc Psychopharmacol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14740338.2016.1229301","article-title":"Second generation antipsychotics in 'real-life' paediatric patients. Adverse drug reactions and clinical outcomes of drug switch","volume":"15","author":"Rafaniello","year":"2016","journal-title":"Exp Opin Drug Saf"},{"key":"B21","unstructured":"Off-label use of atypical antipsychotics: an update\n            MaglioneM\n            MaherAR\n            HuJ\n            WangZ\n            ShanmanR\n            ShekellePG\n          22132426Rockville (MD)Agency for Healthcare Research and Quality (US)2011"},{"key":"B22","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1007\/BF03261977","article-title":"Patient versus healthcare professional spontaneous adverse drug reaction reporting: a systematic review","volume":"35","author":"Inch","year":"2012","journal-title":"Drug Saf. Oct."},{"key":"B23","doi-asserted-by":"publisher","first-page":"19","DOI":"10.2165\/00002018-200932010-00002","article-title":"Determinants of under-reporting of adverse drug reactions: a systematic review","volume":"32","author":"Lopez-Gonzalez","year":"2009","journal-title":"Drug Saf."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/00002018-200225010-00001","article-title":"Unlicensed and off-label drug use in children: implications for safety","volume":"25","author":"Choonara","year":"2002","journal-title":"Drug Saf."},{"key":"B25","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1089\/cap.2018.0024","article-title":"Use and characteristics of antipsychotic\/methylphenidate combination therapy in children and adolescents with a diagnosis of attention-deficit\/hyperactivity disorder","volume":"28","author":"Scholle","year":"2018","journal-title":"J Child Adolesc Psychopharmacol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1177\/070674371506000203","article-title":"The pharmacological management of oppositional behaviour, conduct problems, and aggression in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, and conduct disorder: a systematic review and meta-analysis. Part. (2015) 2: antipsychotics and traditional mood stabilizers","volume":"60","author":"Pringsheim","year":"","journal-title":"Can J Psychiatry."},{"key":"B27","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1089\/cap.2018.0037","article-title":"A Focused review on the treatment of pediatric patients with atypical antipsychotics","volume":"28","author":"Lee","year":"2018","journal-title":"J Child Adolesc Psychopharmacol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/bdi.12609","article-title":"Canadian network for mood and anxiety treatments (CANMAT) and international society for bipolar disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder","volume":"20","author":"Yatham","year":"2018","journal-title":"Bipolar Disord."},{"key":"B29","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1089\/cap.2014.0166","article-title":"Placebo-controlled trial of valproic Acid versus risperidone in children 3-7 years of age with bipolar I disorder","volume":"25","author":"Kowatch","year":"2015","journal-title":"J Child Adolesc Psychopharmacol."},{"key":"B30","unstructured":"Farmaci con evidenza scientifica a supporto dell'uso in pediatria per indicazioni terapeutiche diverse da quelle autorizzateAllegato P82019"},{"key":"B31","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.chc.2016.12.014","article-title":"Schizophrenia and psychosis: diagnosis, current research trends, and model treatment approaches with implications for transitional age youth","volume":"26","author":"Chan","year":"2017","journal-title":"Child Adolesc Psychiatr Clin N Am."},{"key":"B32","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1055\/s-0031-1286348","article-title":"U. Aripiprazole in children and adolescents with conduct disorder: a single-center, open-label study","volume":"45","author":"Ercan","year":"2012","journal-title":"Pharmacopsychiatry."},{"key":"B33","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1097\/01.chi.0000246060.62706.af","article-title":"Practice parameter for the assessment and treatment of children and adolescents with oppositional defiant disorder","volume":"46","author":"Steiner","year":"2007","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"B34","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1097\/JCP.0000000000000548","article-title":"Neurological, metabolic, and psychiatric adverse events in children and adolescents treated with aripiprazole","volume":"36","author":"Jakobsen","year":"2016","journal-title":"J Clin Psychopharmacol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1089\/cap.2020.0014","article-title":"Aripiprazole in children and adolescents","volume":"15","author":"Coustals","year":"2020","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1177\/2045125311419552","article-title":"Psychotic exacerbation and emotional dampening in the daily life of patients with schizophrenia switched to aripiprazole therapy: a collection of standardized case reports","volume":"1","author":"Lataster","year":"2011","journal-title":"Ther Adv Psychopharmacol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s00213-013-3154-1","article-title":"A systematic review of reported cases involving psychotic symptoms worsened by aripiprazole in schizophrenia or schizoaffective disorder","volume":"228","author":"Takeuchi","year":"2013","journal-title":"Psychopharmacology."},{"key":"B38","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3390\/jcm8122203","article-title":"Hyperprolactinaemia","volume":"8","author":"Samperi","year":"2019","journal-title":"J Clin Med."},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2020.1713091","article-title":"Update on weight-gain caused by antipsychotics: a systematic review and meta-analysis","author":"Barton","year":"2020","journal-title":"Expert Opin Drug Saf"},{"key":"B40","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s40801-019-0151-7","article-title":"SL. Adverse events associated with risperidone use in pediatric patients: a retrospective biobank study","volume":"6","author":"Oshikoya","year":"2019","journal-title":"Drugs Real World Outcomes."},{"key":"B41","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1097\/01.chi.0000220851.94392.30","article-title":"Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents","volume":"45","author":"Correll","year":"2006","journal-title":"J Am Acad Child Adolesc Psychiatry."},{"key":"B42","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1177\/0706743717718166","article-title":"Long-term metabolic effects in french-canadian children and adolescents treated with second-generation antipsychotics in monotherapy or polytherapy: a 24-month descriptive retrospective study","volume":"62","author":"Ilies","year":"2017","journal-title":"Can J Psychiatry."},{"key":"B43","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.jaac.2014.05.010","article-title":"Growth in the concurrent use of antipsychotics with other psychotropic medications in Medicaid-enrolled children","volume":"53","author":"Kreider","year":"2014","journal-title":"J Am Acad Child Adolesc Psychiatr."},{"key":"B44","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1001\/jamapsychiatry.2018.4320","volume":"76","author":"Tiihonen","year":"2019","journal-title":"JAMA Psychiatry."},{"key":"B45","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1002\/phar.1453","article-title":"Antipsychotic polypharmacy in children and adolescents at discharge from psychiatric hospitalization","volume":"34","author":"Salda\u00f1a","year":"2014","journal-title":"Pharmacotherapy."},{"key":"B46","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1080\/14740338.2019.1598969","article-title":"Surveillance of adverse events following immunization related to human papillomavirus vaccines: 12 years of vaccinovigilance in Southern Italy","volume":"18","author":"Scavone","year":"2019","journal-title":"Expert Opin Drug Saf."}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2020.550201\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,2]],"date-time":"2020-12-02T04:46:07Z","timestamp":1606884367000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2020.550201\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,2]]},"references-count":46,"alternative-id":["10.3389\/fpsyt.2020.550201"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2020.550201","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,2]]},"article-number":"550201"}}